Adherex Technologies Inc. (NASDAQ:FENC), a key player in the Medical - Biomedical and Genetics industry, is focused on developing and commercializing innovative therapies. Despite its efforts, FENC faces challenges in meeting financial expectations, as seen in its recent earnings report. The company competes with other firms in the biomedical sector, striving to improve its financial performance.
On March 10, 2025, FENC reported an earnings per share (EPS) of -$0.06, missing the estimated EPS of $0.56. This result marks a significant negative surprise of 110.71%, as highlighted by Zacks. However, it is an improvement from the previous year's loss of $0.10 per share. Over the past four quarters, FENC has consistently failed to exceed consensus EPS estimates, indicating ongoing financial struggles.
FENC's revenue for the quarter was approximately $7.91 million, below the estimated $8.44 million. This represents a decline from the $9.74 million reported in the same quarter the previous year. The company has only surpassed consensus revenue estimates once in the last four quarters, reflecting its difficulty in achieving revenue growth.
The company's financial ratios further highlight its challenges. FENC has a negative price-to-earnings (P/E) ratio of approximately -140.84, indicating a lack of profitability. The price-to-sales ratio is 3.24, suggesting investors are willing to pay $3.24 for every dollar of sales. The enterprise value to sales ratio is 3.07, slightly lower than the price-to-sales ratio, reflecting the company's valuation including debt and excluding cash.
Despite these challenges, FENC maintains a strong current ratio of 7.80, indicating a solid ability to cover short-term liabilities with short-term assets. However, the debt-to-equity ratio is significantly negative at -6.21, suggesting more liabilities than equity. The enterprise value to operating cash flow ratio is 6.41, showing how many times the operating cash flow can cover the enterprise value.
